Industry News
PolyNovo commences wound treatment trial
Calzada (ASX:CZD) unit PolyNovo will soon trial its BTM technology as an implant to treat major burns and other full thickness wounds requiring a skin graft. [ + ]
Corals ‘could survive a more acidic ocean’
Corals may be better placed to cope with the gradual acidification of the world’s oceans than previously thought, giving rise to hopes that coral reefs might escape climatic devastation. [ + ]
New institute to lead the way on climate change research
A new research institute at the University of Western Sydney (UWS) will use world-class facilities to deliver research that will help Australia tackle the impacts of climate change. [ + ]
Slideshow: Lorne Infection and Immunity
Shots from the Lorne Infection and Immunity conference held in February this year. [ + ]
Study identifies optimal gene targets for new colon cancer test
A study presented by Mayo Clinic researchers at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago has identified two genes that are optimal targets to be analysed in a new noninvasive test for colorectal cancer. [ + ]
Newcastle scientists one step closer to Alzheimer’s blood test
An interdisciplinary team of scientists at the University of Newcastle has shown the potential of a simple blood-based test to identify people in the early stages of Alzheimer’s disease, before any symptoms appear. [ + ]
Changes to IP laws explained
How the changes in the 'Raising the Bar' Bill to intellectual property legislation will affect life science companies. [ + ]
Early data show Bionomics' BNC105 effective against tumours
Preclinical data shows Bionomics' (ASX:BNO) BNC105 compound can be effective in treating platinum-resistant ovarian cancer tumours. [ + ]
IQnovate to move to ASX
Contract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX. [ + ]
Remember me: immune cell discovery could improve vaccines
Researchers at the Walter and Eliza Hall Institute have revealed the process by which a specialised immune cell produces immune memory, which could lead to improvements in vaccines. [ + ]
Merged drug developer nears ASX listing
Bioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April. [ + ]
Pharmaxis signs EU distribution deal for Bronchitol
Pharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe. [ + ]
Agenix on track for hepatitis B drug trial
Melbourne's Agenix (ASX:AGX) expects to be on time with an application to conduct a phase I trial of a prospective hepatitis B treatment in China. [ + ]
Synchrotron funding to support ongoing research
The Australian Synchrotron has yesterday secured a $100 million, allowing the Melbourne-based facility to continue research, after the Federal and state governments pledged contributions. [ + ]
Biota antiviral batters the common cold
Biota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir. [ + ]
